2011 CNMSRS Abstracts

December 2011
Clinical & Investigative Medicine;Dec2011, Vol. 34 Issue 6, p1
Academic Journal
The article presents abstracts on medical topics which include "Dispensing Geographies: Understanding the Realities of Distance, Telehealth, and Oncology Pharmacy Practices in Northern British Columbia" by Ashley Bakker, "Bevacizumab and Ranibizumab for Neovascular Age-Related Macular Degeneration: A Treatment Approach Based on Individual Patient Needs" by Claudine Bellerive and "Survey Study of Primary Health Care Usage and Experience in the Gay Male Population of Winnipeg" by Cal Bergen.


Related Articles

  • Light dims on off-label use of bevacizumab in AMD.  // PharmacoEconomics & Outcomes News;8/4/2012, Issue 659, p2 

    The article reports on the decision of a group of primary care trusts to terminate a policy that provide funds for the off-label use of bevacizumab for the treatment of wet age-related macular degeneration in Southern England.

  • Intraocular inflammation following intravitreal injection of bevacizumab. Sophie Bakri; Theresa Larson; Albert Edwards // Graefe's Archive of Clinical & Experimental Ophthalmology;May2008, Vol. 246 Issue 5, p779 

    Abstract Background  Injection of drugs into the vitreous can lead to intraocular inflammation through infectious and non-infectious processes. Failure to recognize an eye with anterior chamber and vitreous cell as sterile inflammation can lead to unnecessary treatment for...

  • Ranibizumab and Bevacizumab for AMD.  // New England Journal of Medicine;12/8/2011, Vol. 365 Issue 23, p2237 

    No full text rights to any articles when data is not provided by the publisher.

  • Retreatment with Anti-VEGF After Stabilization of AMD.  // Review of Ophthalmology;Oct2012, Vol. 19 Issue 10, p80 

    The article informs that retreatment with anti-vascular endothelial growth factor (VEGF) is required for patients with neo-vascular age-related macular degeneration after a year of the drug Bevacizumab administration.

  • Bevacizumab/pegaptanib/ranibizumab.  // Reactions Weekly;8/28/2010, Issue 1316, p12 

    The article describes the cases of 19 elderly patients who developed retinal pigment epithelial (RPE) tears after receiving pegaptinib, ranibizumab or bevacizumab for macular degeneration.

  • Doctors in England want to use Avastin routinely for wet AMD.  // PharmacoEconomics & Outcomes News;Feb2015, Vol. 722 Issue 1, p2 

    The article reports on the request of physicians in England towards the off-label utilization of Avastin or bevacizumab for wet age-related macular degeneration (AMD) through its approval by the Department of Health, National Health Service (NHS) and the General Media Council.

  • Fruit That's Plum Good for Health and Taste. Schepers, Anastasia // Environmental Nutrition;May2006, Vol. 29 Issue 5, p8 

    The article discusses the therapeutic benefits of plums. The Chinese used smoked plums to quell nausea, reduce fevers and quiet coughs. Plums are used to remove tumors since 25 B.C. The high phenolic content in the fruit makes it an antioxidant. It can also offer protection against age-related...

  • Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Markus Ladewig; Stefanie Karl; Victoria Hamelmann; Hans-Martin Helb; Hendrik Scholl; Frank Holz; Nicole Eter // Graefe's Archive of Clinical & Experimental Ophthalmology;Jan2008, Vol. 246 Issue 1, p17 

    Abstract Background  Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD). Methods  A prospective non-randomized...

  • Avastin could potentially result in huge cost savings in the UK.  // PharmacoEconomics & Outcomes News;5/26/2012, Issue 654, p2 

    The article discusses research on the effectiveness of avastin for treating wet age-related macular degeneration (AMD) which could result to huge cost savings in Great Britain.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics